newsfilter
← Latest News
ACCESS Newswire·

CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / December 8, 2025 / CASI Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing CID-103, a potentially best-in-class, anti-CD38